sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
As evidence accumulates that atherogenesis or Coronary Artery Disease (CAD) may not be simply
a disorder of lipid metabolism, but an inflammatory disease, the focus of treatment has
shifted. A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute
diseases. It acts by inhibiting secretory phospholipase A2 (sPLA2 ) - one of a family of
enzymes leading to inflammation - which may be important in: 1) the development of
atherosclerosis and 2) the increase in occurence of cardiovascular events after angioplasty.
Previous studies have demonstrated that sPLA2: 1) facilitates the pro-atherogenic effects of
low-density (LDL or bad cholesterol) and 2) increased levels post-angioplasty correlate with
an increased risk of events at followup contact. Therefore this study proposes to investigate
the ability of A-002 to prevent or reduce myocardial damage after angioplasty by inhibiting
the cascade of inflammatory mediators.
Substudy - Subjects who agree will also have a vascular ultrasound 24h post-PCI to assess
endothelial function.